- Home
- RDNW vs CUE Comparison
RDNW vs CUE Comparison
Compare RDNW & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDNW | CUE |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.7M | 233.5M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RDNW | CUE |
|---|---|---|
| Price | $5.77 | $28.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.50 | ★ $120.00 |
| AVG Volume (30 Days) | 64.5K | ★ 202.0K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.84 | ★ 61.11 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $1,793,369,000.00 | $27,466,000.00 |
| Revenue This Year | $9.01 | N/A |
| Revenue Next Year | $6.53 | N/A |
| P/E Ratio | $98.33 | ★ N/A |
| Revenue Growth | 91.10 | ★ 195.75 |
| 52 Week Low | $3.20 | $0.17 |
| 52 Week High | $8.55 | $45.50 |
Technical Indicators
Market Signals| Indicator | RDNW | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 52.45 |
| Support Level | $5.70 | $24.70 |
| Resistance Level | $6.23 | $33.95 |
| Average True Range (ATR) | 0.34 | 3.76 |
| MACD | -0.04 | 0.19 |
| Stochastic Oscillator | 22.89 | 53.77 |
Price Performance
Historical ComparisonAbout RDNW RideNow Group Inc.
RideNow Group Inc operates solely as a powersports dealership group. Its offerings include new and pre-owned vehicles such as motorcycles, all-terrain vehicles (ATVs), side-by-side vehicles (SXS), and personal watercraft (PWC). It also sells parts, apparel, and accessories, and provides financing, insurance, and aftermarket products, along with repair and maintenance services. The majority of the company's revenue is derived from powersports vehicle sales, and the rest from parts, service and accessories/merchandise, and finance and insurance products.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.